Spondyloarthritis & psoriatic arthritis
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension
Authors' conclusion
Bimekizumab treatment led to rapid and sustained improvements in key patient symptoms and HRQoL to 3 years
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) (non-radiographic axSpA in BE MOBILE 1; radiographic axSpA in BE MOBILE 2)494 entered open-label extension (OLE)
- Participants
- 586 patients
- Comparison
- Bimekizumab 160 mg subcutaneously every 4 weeks (all patients from week 16), single-group long-term follow-up
- Outcome
- Changes in patient symptoms (spinal pain, morning stiffness, physical function, fatigue, sleep) and health-related quality of life (HRQoL) to 3 years
- Follow-up
- Week 164
Methodological detailsBE MOVING, 16-week double-blind, placebo-controlled period, 36-week maintenance period, 425/494 (86.0%) of OLE entrants completed week 164
- BE MOVING
- 16-week double-blind, placebo-controlled period
- 36-week maintenance period
- 425/494 (86.0%) of OLE entrants completed week 164
Pooled result
As reported in the abstract
Mean change from baseline in symptoms and HRQoL
- Total spinal pain
- −4.3
- Nocturnal spinal pain
- −4.3
- Morning stiffness
- −4.3
- Physical function (Bath Ankylosing Spondylitis Functional Index (BASFI))
- −2.9
- Fatigue (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q1)
- −3.5
- FACIT-Fatigue
- +9.7
- Sleep (MOS-Sleep-R Index II)
- +10.8
- SF-36 Physical Component Summary (PCS)
- +12.3
- Ankylosing Spondylitis Quality of Life (ASQoL)
- −5.6
Further pooled results
Patient-level spinal pain and physical function · to week 164
- Rapid and sustained patient-level improvements observed
Original publication
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. Published 13 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →